Amid growing evidence suggesting circadian rhythms play a critical in the safety and efficacy of CAR T-cell therapy, ...

At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to ...

The bills would require insurers to cover germline multi-gene testing for inherited cancer risk and imaging with no out-of-pocket cost for patients.

The partners will use 4D Path's imaging-based Q-Plasia OncoReader in a Phase II trial testing doublet and triplet regimens comprising Trodelvy, Padcev, and Keytruda.

NEW YORK – Neok Bio on Thursday said it has been cleared by the US Food and Drug Administration to begin a Phase I trial of its bispecific antibody-drug conjugate (ADC) NEOK001 in solid tumors.

NEW YORK – Ocugen said on Friday that it has raised about $22.5 million in a recent public offering.

Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and ...

Mira is bringing its version of Oxford Cancer Biomarkers' PGx test to the US in the newly launched ToxNav Advantage assay.

NEW YORK – Boston Children's Hospital has granted a worldwide license for an investigational gene therapy for sickle cell disease and beta thalassemia to Caring Cross, the nonprofit announced this ...

Janux will conduct preclinical studies of the undisclosed program targeting a validated solid tumor antigen expressed across several cancer types.

The company plans to begin enrolling the trial next quarter across eight US sites to test the vaccine as a monotherapy and in combination with Keytruda.

The firm will conduct a Phase I trial of its KRAS G12D inhibitor in solid tumors and a Phase II trial of its G12C inhibitor plus an ERK1/2 inhibitor in NSCLC.